PFSA · Profusa, Inc.
$2.93
-1.31 (-30.90%)
At close · Aug 28
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, there continue to be factors which raise substantial doubt about the Company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.”View the 10-Q filed Aug 19, 2026
Market Cap
$2.07M
Shares
605,647
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$100K
FY2024
Net Income
-$35.82M
-288.1%
FY2025
Operating Margin
-4500%
FY2024
Diluted EPS
-$10,701.00
+70%
FY2025
Operating Cash Flow
-$16.25M
-686.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | — | $100K | — | — | |
| $3.95M | $2.8M | $1.61M | — | — | |
| $27.88M | $24.9M | $2.99M | — | — | |
| $31.83M | $27.71M | $4.6M | — | — | |
| -$31.83M | -$27.71M | -$4.5M | -$1.51M | -$1.27M | |
| — | — | -4500% | — | — | |
| $232K | $2.52M | $4.42M | — | — | |
| $295.32K | — | $425.42K | $2.25M | $8.94M | |
| -$11.14M | -$8.12M | -$4.73M | $3.13M | $8.94M | |
| -$16.75M | — | -$8.63M | $1.62M | $7.67M | |
| $57.77K | — | $80.51K | $456.79K | $499.21K | |
| -$42.97M | -$35.82M | -$9.23M | $1.16M | $7.17M | |
| — | — | -9230% | — | — | |
| USD/shares | $8,551.98 | -$10,701.00 | -$35,714.00 | $900.00 | $2,250.00 |
| USD/shares | $8,551.98 | -$10,701.00 | -$35,714.00 | $900.00 | $2,250.00 |
| shares | — | 3347.62 | 258.44 | 692.5 | 692.5 |
| shares | — | 3347.62 | 258.44 | 692.5 | 692.5 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2024: $188.09M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.57×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 31 similar-size Medical Devices companies (of 139 listed).